• Successful PARASOL collaboration data analysis outcome announced
• DMX-200 received Orphan Drug Designation in Japan
• Dimerix awarded the 2025 Bioshares Blake Award for second year in a row

Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, announced its Appendix 4C and Quarterly Activities Report for the period ended 30 September 2025 (Q1 FY26). During the quarter, Dimerix continued to make significant progress with advancing its lead product candidate DMX-200 through the ACTION3 Phase 3 clinical trial in FSGS, a rare type of kidney disease. Highlights included substantial progress in patient recruitment, as well as the receipt of orphan drug designation in Japan, which adds to the existing designations in the US, Europe, and UK. Dimerix also announced the receipt of final data analysis under the PARASOL collaboration, which is expected to support potential marketing approval for DMX-200 in territories around the world, including the US. The company ended the quarter with a strong cash position of AU$49.2 million, with net operating cash outflows of AU$18.8 million, which were in line with expectations and included certain clinical trial expenses to be reimbursed, one-off costs associated with milestones and a US licensing transaction, as well as expenditure on new R&D pipeline activities. Dimerix remains focused on advancing the ACTION3 Phase 3 clinical trial and pursuing licensing opportunities with potential partners in territories not already licensed.

Dimerix expects the future quarters to see ACTION3 spend reduced, as the trial nears full recruitment. The company remains well positioned to continue focusing on advancing the ACTION3 Phase 3 clinical trial.